U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C62H86N12O16
Molecular Weight 1255.4194
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DACTINOMYCIN

SMILES

CC(C)[C@]1([H])C(=O)N2CCC[C@@]2([H])C(=O)N(C)CC(=O)N(C)[C@@]([H])(C(C)C)C(=O)O[C@]([H])(C)[C@@]([H])(C(=N1)O)N=C(c3ccc(C)c4c3nc-5c(c(c(=O)c(C)c5o4)N)C(=N[C@@]6([H])[C@@]([H])(C)OC(=O)[C@]([H])(C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@@]([H])(C(C)C)N=C6O)O)O

InChI

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954

Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
156.25 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

-1.59667192E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.3 μg/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
25.1 ng/mL
1.1 mg/m² unknown, intravenous
dose: 1.1 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
142.4 mg × h/L
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.67 μg × min/L
1.1 mg/m² unknown, intravenous
dose: 1.1 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.8 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28.5 h
1.1 mg/m² unknown, intravenous
dose: 1.1 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Other AEs: Pancytopenia, Mucositis...
Other AEs:
Pancytopenia (1 patient)
Mucositis (severe, 1 patient)
Pancreatitis (1 patient)
Hyponatremia (1 patient)
Hypocalcemia (1 patient)
Respiratory distress (1 patient)
Melena (1 patient)
Sources:
0.15 ug/kg multiple, intravenous (total)
Highest studied dose
Dose: 0.15 ug/kg
Route: intravenous
Route: multiple
Dose: 0.15 ug/kg
Sources:
unhealthy, 40-77 years
n = 2
Health Status: unhealthy
Condition: malignant melanoma
Age Group: 40-77 years
Sex: F
Population Size: 2
Sources:
1.5 mg/m2 single, intravenous
Highest studied dose
Dose: 1.5 mg/m2
Route: intravenous
Route: single
Dose: 1.5 mg/m2
Sources:
unknown, children
n = 1
Health Status: unknown
Age Group: children
Population Size: 1
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypocalcemia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Hyponatremia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Melena 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Pancreatitis 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Pancytopenia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Respiratory distress 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Mucositis severe, 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
n = 1
Health Status: unhealthy
Age Group: 18 months
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Veno-occlusive disease of the liver as a treatment complication in children with Wilm's tumor].
1992
Oxidant stress induces gamma-glutamylcysteine synthetase and glutathione synthesis in human bronchial epithelial NCI-H292 cells.
2002 Apr
Effect of actinomycin D on simian rotavirus (SA11) replication in cell culture.
2002 Apr
Pathways of induction of peroxiredoxin I expression in osteoblasts: roles of p38 mitogen-activated protein kinase and protein kinase C.
2002 Apr 5
Induction and superinduction of 2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor.
2002 Aug 15
Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells.
2002 Aug 16
Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells.
2002 Dec
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
2002 Dec 1
Induction of MnSOD gene by arachidonic acid is mediated by reactive oxygen species and p38 MAPK signaling pathway in human HepG2 hepatoma cells.
2002 Jun 1
Functional analysis of MRP1 cloned from bovine.
2002 Jun 19
Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis.
2002 May 17
Differential effects of thyroxine on metabolic enzymes and other macromolecules in a freshwater teleost.
2003 Apr 1
Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells.
2003 Aug
Identification of manganese superoxide dismutase as a NO-regulated gene in rat glomerular mesangial cells by 2D gel electrophoresis.
2003 Dec
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells.
2003 Dec 20
An efficient, nonenzymatic method for isolation and culture of murine aortic endothelial cells and their response to inflammatory stimuli.
2003 Jan-Feb
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
2003 Jun
Regulation of rat intestinal GLUT2 mRNA abundance by luminal and systemic factors.
2003 Jun 10
Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation.
2003 Mar
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes.
2003 Mar
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.
2003 Mar 15
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.
2003 May
Interplay between transcriptional and post-transcriptional regulation of Cyp2a5 expression.
2003 May 15
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells.
2003 May 15
Zinc modulates mRNA levels of cytokines.
2003 Nov
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
2003 Oct
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.
2003 Oct 3
Thyroid hormone activates fibroblast growth factor receptor-1 in bone.
2003 Sep
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling.
2003 Sep 5
Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors.
2004 Aug
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.
2004 Dec
Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.
2004 Dec
Dactinomycin-induced veno-occlusive disease in rats. The hepatoprotective action of amifostine. Evaluation in a light and electron microscope.
2004 Feb
Cytoprotective effects of heme oxygenase-1 induction by 3-O-caffeoyl-1-methylquinic acid.
2004 Jan 1
Mechanism of heme oxygenase-1 gene induction by quercetin in rat aortic smooth muscle cells.
2004 Jun
Induction of manganese-superoxide dismutase by YS 51, a synthetic 1-(beta-naphtylmethyl)6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline alkaloid: implication for anti-inflammatory actions.
2004 Jun
Endosulfan-mediated biochemical changes in the freshwater fish Clarias batrachus.
2004 Mar
Overexpression of phospholipase D prevents actinomycin D-induced apoptosis through potentiation of phosphoinositide 3-kinase signalling pathways in Chinese-hamster ovary cells.
2004 Mar 1
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004 Nov
2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents.
2004 Sep 20
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats.
2004 Sep-Oct
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
2005 Apr
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
2005 Feb 10
Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells.
2005 Feb 25
Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells.
2005 Jan 1
Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.
2005 Jan 14
Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists.
2005 Jan 28
Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression.
2005 Mar
Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance.
2005 Mar 1
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors.
2005 May
Patents

Sample Use Guides

Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/25932119
Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.
Name Type Language
DACTINOMYCIN
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
DACTINOMYCIN [HSDB]
Common Name English
ACTINOMYCIN C1
Common Name English
ACTINOMYCIN D [WHO-IP]
Common Name English
DACTINOMYCIN [WHO-IP]
Common Name English
3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-
Common Name English
ACTINOMYCIN-D
Common Name English
ACTINOMYCIN I1
Common Name English
DILACTONE ACTINOMYCIN D ACID
Common Name English
ACTINOMYCIN D [JAN]
Common Name English
DACTINOMYCIN [USP-RS]
Common Name English
GNF-PF-2290
Code English
DACTINOMYCIN [USP MONOGRAPH]
Common Name English
ACTINOMYCIN D [IARC]
Common Name English
DACTINOMYCIN [MART.]
Common Name English
DACTINOMYCIN [USAN]
Common Name English
DACTINOMYCIN [VANDF]
Common Name English
MERACTINOMYCIN
Common Name English
ACTINOMYCIN X1
Common Name English
DACTINOMYCINUM [WHO-IP LATIN]
Common Name English
DACTINOMYCIN [MI]
Common Name English
DACTINOMYCIN [ORANGE BOOK]
Common Name English
DACTINOMYCIN [WHO-DD]
Common Name English
N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE
Common Name English
NSC-3053
Code English
ACTINOMYCIN D
WHO-IP  
Common Name English
NCI-C04682
Code English
ACTINOMYCIN IV
Common Name English
DACTINOMYCIN [INN]
Common Name English
ONCOSTATIN K
Common Name English
COSMEGEN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C204
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
NDF-RT N0000000233
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
LIVERTOX 258
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
IARC Actinomycin D
NDF-RT N0000000150
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
NDF-RT N0000180850
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
WHO-ATC L01DA01
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
WHO-VATC QL01DA01
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
Code System Code Type Description
HSDB
3220
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
PUBCHEM
457193
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
DRUG BANK
DB00970
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
MERCK INDEX
M4067
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY Merck Index
LACTMED
Dactinomycin
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
EVMPD
SUB129914
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
CAS
50-76-0
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
FDA UNII
1CC1JFE158
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
NCI_THESAURUS
C412
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-063-6
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
EPA CompTox
50-76-0
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DACTINOMYCIN
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY Description: An orange-red to red, crystalline powder.Solubility: Soluble in water at 10 ?C and slightly soluble in water at 37 ?C; freely soluble in ethanol (~750 g/l) TS and methanol R;very slightly soluble in ether R.Category: Cytotoxic drug.Storage: Dactinomycin should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 40 ?C.Additional information: Dactinomycin is hygroscopic and is affected by light and heat.CAUTION: Dactinomycin must be handled with care, avoiding contact with the skin and inhalation of airborne particles.
EVMPD
SUB13528MIG
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
USP_CATALOG
1162400
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY USP-RS
MESH
D003609
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
ChEMBL
CHEMBL1554
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
INN
1155
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY
RXCUI
3100
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
774
Created by admin on Fri Jun 25 20:57:37 UTC 2021 , Edited by admin on Fri Jun 25 20:57:37 UTC 2021
PRIMARY